Coherus BioSciences Inc (CHRS) — Cash Flow Quality Index
Coherus BioSciences Inc (CHRS) has a Cash Flow Quality Index of -0.08x as of December 2025. Operating cash flow of $-19.72 Million is below net income of $241.20 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore CHRS cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Coherus BioSciences Inc Cash Flow Quality Index (2019–2025)
Historical Cash Flow Quality Index for Coherus BioSciences Inc across 4 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see cash flow conversion of Coherus BioSciences Inc.
Annual Cash Flow Quality Index for Coherus BioSciences Inc (2019–2025)
Year-by-year earnings quality comparison for Coherus BioSciences Inc.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | -0.82x | $-138.51 Million | $168.02 Million | ▼ -15.0% |
| 2024 | -0.72x | $-20.44 Million | $28.51 Million | ▼ -161.5% |
| 2020 | 1.17x | $154.15 Million | $132.24 Million | ▲ +269.3% |
| 2019 | 0.32x | $28.36 Million | $89.83 Million | — |